Dosing illustration




BRAFTOVI®️ and MEKTOVI®️ are available in packs of:

BRAFTOVI®️* 75 mg 42 x 1 hard capsules
BRAFTOVI®️* 75 mg 168 x 1 hard capsules
MEKTOVI®️ 15 mg 84 film-coated tablets

*Not all pack sizes may be marketed

For patients undergoing dose reduction BRAFTOVI®️ is also available in 50mg capsules

Recommended dosing

Recommended dosing


Treatment with BRAFTOVI®️ + MEKTOVI®️ should be continued until the patient no longer derives benefit or the development of unacceptable toxicity.

a For patients with mild hepatic impairment, administration of BRAFTOVI should be undertaken with caution at a reduced dose. In the absence of clinical data, BRAFTOVI is not recommended in patients with moderate to severe hepatic impairment.1

Recommended dose adjustments

BRAFTOVI® + MEKTOVI® are indicated to be taken in combination.

The management of ARs may require dose reduction, temporary interruption, or treatment discontinuation.

Dose adjustments

Dose modifications are recommended to manage certain adverse reactions.

aThere are limited data for dose reduction to 100 mg QD. If unable to tolerate 100 mg QD, permanently discontinue BRAFTOVI.1
bIf unable to tolerate 30 mg BID, permanently discontinue MEKTOVI.1 BID, twice daily; QD, once daily. 

Patient monitoring is recommended prior, during and after the treatment. For more information on safety, explore our Therapy Management Guide, on the Support and Resources page.


Dose interruption and discontinuation

When temporarily interrupting or permanently discontinuating BRAFTOVI or MEKTOVI, please adapt the other drug's posology according to the table below.

dose interruption and discontinuation

For complete information, please refer to the Summaries of Product Characteristics.

HealthCare Professionals​

This is an international website for BRAFTOVI® + MEKTOVI® dedicated to Healthcare professionals ​​

IMPORTANT: the information on this website is based on the European Summary of Product Characteristics. Prescribing Information and indication may vary per country. You must refer to your country prescribing information. Please be aware we do not take responsibility for accessing such information which may not comply with the regulation or usage in your country.

I certify that: 

I am Healthcare Professional outside the US and I have read the information above​.


This is an international website for BRAFTOVI® + MEKTOVI® dedicated to Healthcare Professionals.

I am a patient outside the US​.